Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

My NCBI Filters
Text availability
Article attribute
Article type
Publication date

Search Results

232 results
Filters applied: . Clear all Results are displayed in a computed author sort order. Results by year timeline is unavailable
Page 1
Phase 1 study of mTORC1/2 inhibitor sapanisertib (TAK-228) in advanced solid tumours, with an expansion phase in renal, endometrial or bladder cancer.
Voss MH, Gordon MS, Mita M, Rini B, Makker V, Macarulla T, Smith DC, Cervantes A, Puzanov I, Pili R, Wang D, Jalal S, Pant S, Patel MR, Neuwirth RL, Enke A, Shou Y, Sedarati F, Faller DV, Burris HA 3rd. Voss MH, et al. Among authors: burris ha 3rd. Br J Cancer. 2020 Sep 11. doi: 10.1038/s41416-020-01041-x. Online ahead of print. Br J Cancer. 2020. PMID: 32913286 Free article.
2020 ASCO Presidential Address: Unite and Conquer-Accelerating Progress Together.
Burris HAS 3rd. Burris HAS 3rd. J Clin Oncol. 2020 Aug 20;38(24):2703-2705. doi: 10.1200/JCO.20.01684. Epub 2020 Jul 10. J Clin Oncol. 2020. PMID: 32650685 No abstract available.
Phase I Study of TAK-659, an Investigational, Dual SYK/FLT3 Inhibitor, in Patients with B-Cell Lymphoma.
Gordon LI, Kaplan JB, Popat R, Burris HA 3rd, Ferrari S, Madan S, Patel MR, Gritti G, El-Sharkawi D, Chau I, Radford JA, Pérez de Oteyza J, Zinzani PL, Iyer S, Townsend W, Karmali R, Miao H, Proscurshim I, Wang S, Wu Y, Stumpo K, Shou Y, Carpio C, Bosch F. Gordon LI, et al. Among authors: burris ha 3rd. Clin Cancer Res. 2020 Jul 15;26(14):3546-3556. doi: 10.1158/1078-0432.CCR-19-3239. Epub 2020 Apr 23. Clin Cancer Res. 2020. PMID: 32327472 Free article.
A Phase II Open Label Study of Everolimus in Combination With Endocrine Therapy in Resistant Hormone Receptor-Positive HER2-Negative Advanced Breast Cancer.
Yardley DA, Liggett W, Mainwaring M, Castrellon A, Blakely L, Hemphill B, Anz B 3rd, Young RR, Shastry M, DeBusk LM, Hainsworth JD, Burris HA 3rd. Yardley DA, et al. Among authors: burris ha 3rd. Clin Breast Cancer. 2020 Apr;20(2):89-97. doi: 10.1016/j.clbc.2019.06.005. Epub 2019 Jun 26. Clin Breast Cancer. 2020. PMID: 31932237
Correcting the ASCO position on phase I clinical trials in cancer.
Burris HA 3rd. Burris HA 3rd. Nat Rev Clin Oncol. 2020 Feb;17(2):125. doi: 10.1038/s41571-019-0311-4. Nat Rev Clin Oncol. 2020. PMID: 31857691 No abstract available.
Phase Ia Study of Anti-NaPi2b Antibody-Drug Conjugate Lifastuzumab Vedotin DNIB0600A in Patients with Non-Small Cell Lung Cancer and Platinum-Resistant Ovarian Cancer.
Gerber DE, Infante JR, Gordon MS, Goldberg SB, Martín M, Felip E, Martinez Garcia M, Schiller JH, Spigel DR, Cordova J, Westcott V, Wang Y, Shames DS, Choi Y, Kahn R, Dere RC, Samineni D, Xu J, Lin K, Wood K, Royer-Joo S, Lemahieu V, Schuth E, Vaze A, Maslyar D, Humke EW, Burris HA 3rd. Gerber DE, et al. Among authors: burris ha 3rd. Clin Cancer Res. 2020 Jan 15;26(2):364-372. doi: 10.1158/1078-0432.CCR-18-3965. Epub 2019 Sep 20. Clin Cancer Res. 2020. PMID: 31540980 Clinical Trial.
A Randomized, Double-Blinded, Phase II Trial of Carboplatin and Pemetrexed with or without Apatorsen (OGX-427) in Patients with Previously Untreated Stage IV Non-Squamous-Non-Small-Cell Lung Cancer: The SPRUCE Trial.
Spigel DR, Shipley DL, Waterhouse DM, Jones SF, Ward PJ, Shih KC, Hemphill B, McCleod M, Whorf RC, Page RD, Stilwill J, Mekhail T, Jacobs C, Burris HA 3rd, Hainsworth JD. Spigel DR, et al. Among authors: burris ha 3rd. Oncologist. 2019 Dec;24(12):e1409-e1416. doi: 10.1634/theoncologist.2018-0518. Epub 2019 Aug 16. Oncologist. 2019. PMID: 31420467 Free PMC article. Clinical Trial.
WITHDRAWN: Cardio-Oncology: Stronger Together.
Kovacs RJ, Burris HA 3rd. Kovacs RJ, et al. Among authors: burris ha 3rd. J Am Coll Cardiol. 2019 Jul 31:S0735-1097(19)36086-3. doi: 10.1016/j.jacc.2019.07.041. Online ahead of print. J Am Coll Cardiol. 2019. PMID: 31404608
Phase I/II study of bevacizumab with BKM120, an oral PI3K inhibitor, in patients with refractory solid tumors (phase I) and relapsed/refractory glioblastoma (phase II).
Hainsworth JD, Becker KP, Mekhail T, Chowdhary SA, Eakle JF, Wright D, Langdon RM, Yost KJ, Padula GDA, West-Osterfield K, Scarberry M, Shaifer CA, Shastry M, Burris HA 3rd, Shih K. Hainsworth JD, et al. Among authors: burris ha 3rd. J Neurooncol. 2019 Sep;144(2):303-311. doi: 10.1007/s11060-019-03227-7. Epub 2019 Aug 7. J Neurooncol. 2019. PMID: 31392595 Clinical Trial.
Trastuzumab emtansine with or without pertuzumab versus trastuzumab with taxane for human epidermal growth factor receptor 2-positive advanced breast cancer: Final results from MARIANNE.
Perez EA, Barrios C, Eiermann W, Toi M, Im YH, Conte P, Martin M, Pienkowski T, Pivot XB, Burris HA 3rd, Petersen JA, De Haas S, Hoersch S, Patre M, Ellis PA. Perez EA, et al. Among authors: burris ha 3rd. Cancer. 2019 Nov 15;125(22):3974-3984. doi: 10.1002/cncr.32392. Epub 2019 Jul 18. Cancer. 2019. PMID: 31318460
232 results
Jump to page
Feedback